


# Get started now with AI-driven precision pathology

Enable tissue biomarker  
analysis and standardization  
for diagnostic decision support





# Wherever you are on your digital journey, Visiopharm can support you in realizing the benefits of AI-driven precision pathology.

AI-driven Precision Pathology can improve diagnostic accuracy for biomarker evaluation. Visiopharm's diagnostic APPs have been developed in close collaboration with pathologists and are certified under IVDR. The APP from DeepBio is IVDD.

No matter your digital progress, our APPs can enhance your current workflow and setup. Full integration is supported for various PACS/IMS/LIS systems, including Fujifilm, Sectra, Proscia, INFINITT, Paige and more, allowing you to review the analysis within your primary viewer.

Alternatively, a stand-alone installation can get you started immediately.

Analyze images with high accuracy and speed on a foundation of quality, enabling you to spend more time focusing on the interpretation of the results to get the answers you need.



**QUALITOPIX**

Web

Trust your staining consistency

**ONCOTOPIX**


Web & deployed

No matter your progress in the digital journey, get started now with precision pathology

Pre-analyzed slides – ready for your review


Reproducible and accurate biomarker quantification

Our AI-based image analysis APPs provide precise quantifications to assess biomarker expressions for diagnostic decision support in various cancer indications.




### Ki-67, breast cancer

Our Ki-67 APP detects nuclei in the invasive tumor only, returning a proliferation index for the entire tumor region. It can be combined with the Hot Spot detection APP.




### HER2, breast cancer

For HER2 in breast cancer, our APP measures the connectivity of the membrane staining and exports the classic HER2 Score as well as a continuous connectivity score.




### ER & PR, breast cancer

These two APPs measure ER and PR positivity in breast cancer and provide the number of total, positive and negative nuclei as well as an Allred score.




### Lymph node metastasis, breast & colon cancer

The APP detects even small and not easily noticed metastases in lymph nodes associated with breast and colon adenocarcinoma, stained with H&E.



### Prostate cancer, detection and grading, H&E

The APP from Deep Bio (IVDD) detects invasive tumor areas in needle core biopsies of prostate cancer, stained with H&E, and grades according to the Gleason Scoring System.




### PD-L1, lung cancer (NSCLC)

For PD-L1 in non-small cell lung cancer (NSCLC), our APP evaluates the whole tumor section and returns the global Tumor Proportion Score (TPS).



## Solution configurations



## Visiopharm


We are a leading provider of AI-driven precision pathology software for research and diagnostics.

In research, we are a technology leader providing tools that help scientists, pathologists, and image analysis experts produce accurate data for all types of tissue-based research.

In diagnostics, we are a leader within clinical applications, with no less than nine diagnostic algorithms cleared under IVDR for EU/UK customers. These applications provide

diagnostic decision support and can be easily activated and integrated into existing lab workflows.

Founded in 2002, we are privately owned and operate internationally with over 750 customer accounts in more than 40 countries. Our headquarters are located in Denmark's Medicon Valley, with offices in Sweden, the UK, Germany, the Netherlands, and the United States, and local representation in France and China.



Visiopharm A/S  
 Agern Allé 24  
 2970 Hørsholm, Denmark  
 visiopharm.com



Book a demo